$1.05
19.23% day before yesterday
Nasdaq, Jul 11, 07:33 pm CET
ISIN
US68619K2042
Symbol
ORGS
Sector
Industry

Orgenesis Inc. Stock price

$1.07
-1.09 50.46% 1M
-0.55 33.95% 6M
-0.82 43.39% YTD
-5.64 84.05% 1Y
-21.43 95.24% 3Y
-55.33 98.10% 5Y
-52.92 98.02% 10Y
+0.69 183.74% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.23 17.69%
ISIN
US68619K2042
Symbol
ORGS
Sector
Industry

Key metrics

Basic
Market capitalization
$5.5m
Enterprise Value
$20.5m
Net debt
$15.0m
Cash
$200.0k
Shares outstanding
4.8m
Valuation (TTM | estimate)
P/E
negative | -
P/S
6.1 | -
EV/Sales
22.8 | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-144.2%
Return on Equity
263.8%
ROCE
411.7%
ROIC
-505.2%
Debt/Equity
-0.6
Financials (TTM | estimate)
Revenue
$900.0k | -
EBITDA
$-24.9m | -
EBIT
$-26.2m | -
Net Income
$-34.4m | -
Free Cash Flow
$-15.7m
Growth (TTM | estimate)
Revenue
-96.8% | -
EBITDA
-240.4% | -
EBIT
-210.2% | -
Net Income
-37.3% | -
Free Cash Flow
51.8%
Margin (TTM | estimate)
Gross
-97.7%
EBITDA
-2,767.6% | -
EBIT
-2,912.6%
Net
-3,827.8% | -
Free Cash Flow
-1,750.2%
More
EPS
$-7.3
FCF per Share
$-3.3
Short interest
1.3%
Employees
146
Rev per Employee
$0.0
Show more

Is Orgenesis Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Orgenesis Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Orgenesis Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Orgenesis Inc. forecast:

Buy
86%
Hold
14%

Financial data from Orgenesis Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.90 0.90
97% 97%
100%
- Direct Costs 1.78 1.78
73% 73%
198%
-0.88 -0.88
104% 104%
-98%
- Selling and Administrative Expenses 12 12
38% 38%
1,286%
- Research and Development Expense 13 13
25% 25%
1,389%
-25 -25
240% 240%
-2,764%
- Depreciation and Amortization 1.30 1.30
15% 15%
144%
EBIT (Operating Income) EBIT -26 -26
210% 210%
-2,909%
Net Profit -34 -34
37% 37%
-3,823%

In millions USD.

Don't miss a Thing! We will send you all news about Orgenesis Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Orgenesis Inc. Stock News

Neutral
Accesswire
4 months ago
Strategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments GERMANTOWN, MD / ACCESS Newswire / March 6, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced the acquis...
Neutral
Accesswire
6 months ago
Funding Aimed at Accelerating Rollout of Decentralized CGT Platform GERMANTOWN, MD / ACCESS Newswire / January 28, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that it has concluded an agreement for an equity...

Company Profile

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Head office United States
CEO Vered Caplan
Employees 146
Founded 2008
Website www.orgenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today